"10.1371_journal.pone.0068273","plos one","2013-07-02T00:00:00Z","Matti Förster; Friederike Mahn; Ulrich Gockel; Mathias Brosz; Rainer Freynhagen; Thomas R Tölle; Ralf Baron","Sektion Neurologische Schmerzforschung und–therapie, Klinik für Neurologie Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany; Casquar GmbH, Bochum, Germany; StatConsultGmbH, Magdeburg, Germany; Zentrum für Anästhesiologie, Intensivmedizin, Schmerztherapie und Palliativmedizin, Benedictus Krankenhaus Tutzing, Tutzing, Germany; Klinik für Neurologie, Technische Universität München, München, Germany","Conceived and designed the experiments: RB TRT RF MF FM. Performed the experiments: MF FM RB MB. Analyzed the data: MF FM RB. Contributed reagents/materials/analysis tools: UG MB RF TRT RB. Wrote the paper: MF FM UG MB RF TRT RB.","The authors have the following interests. This research was supported by a grant from Pfizer Germany without restriction on publication. Data was collected within the PainDetect project, which was funded by Pfizer. Ulrich Gockel is employed by Casquar GmbH and is a part-time worker for Grünenthal GmbH International medical affairs department. Mathias Brosz is employed by StatConsult GmbH. StatConsult maintains painDETECT, and supports research technically as well as statistically. MB has analyzed the complete data which was held at the central data-processing facility StatConsult GmbH, Magdeburg (Germany). MF is a member of the IMI Europain consortium. He has received speaking fees from Pfizer, Denmark and Grünenthal. FM is a member of the IMI Europain consortium. She has received research support, consulting, or speaking fees from Grünenthal and Pfizer. RF has received research support, consulting or speaking fees from Astellas, Epionics, Forest research, HRA, Grünenthal, Lilly, Boehringer, Pfizer, UCB, Schwarz Pharma. TRT has received consulting and speaking fees from Pfizer, Grünenthal, Lilly, Epionics, UCB, Mundipharma, Pharmaleads. RB receives grants/research support from the following organizations: Pfizer, Genzyme, Grünenthal. RB is a member of the IMI Europain consortium IMI “Europain” collaboration and industry members of this are: Astra Zeneca, Pfizer, Esteve, UCB-Pharma, Sanofi Aventis, Grünenthal, Eli Lilly and Boehringer Ingelheim. He has received speaking fees from Pfizer, Genzyme, Grünenthal, Mundipharma, Sanofi Pasteur, Medtronic, Eisai, UCB BioSciences, Lilly, Boehringer Ingelheim, Astellas, Desitin and Teva Pharma. He has been a consultant to Pfizer, Genzyme, Grünenthal, Mundipharma, Allergan, Sanofi Pasteur, Medtronic, Eisai, UCB BioSciences, Lilly, Boehringer Ingelheim, Astellas, Novartis, Bristol-Myers Squibb, Biogenidec and AstraZeneca. There are no further patents, products in development, or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.",NA,NA,NA,"2013","07","Matti Förster","MF",7,TRUE,5,4,3,7,TRUE,TRUE,FALSE,0,NA,FALSE
